Leerink Partnrs Brokers Lower Earnings Estimates for LENZ

LENZ Therapeutics, Inc. (NASDAQ:LENZ - Free Report) - Investment analysts at Leerink Partnrs dropped their FY2028 earnings per share estimates for shares of LENZ Therapeutics in a research report issued to clients and investors on Thursday, July 10th. Leerink Partnrs analyst M. Goodman now anticipates that the company will post earnings per share of $1.05 for the year, down from their previous forecast of $1.10. The consensus estimate for LENZ Therapeutics' current full-year earnings is ($2.18) per share.

LENZ Therapeutics (NASDAQ:LENZ - Get Free Report) last posted its earnings results on Wednesday, May 7th. The company reported ($0.53) earnings per share for the quarter, topping the consensus estimate of ($0.55) by $0.02.

Several other research firms have also weighed in on LENZ. Citigroup lifted their target price on LENZ Therapeutics from $44.00 to $47.00 and gave the stock a "buy" rating in a report on Thursday, March 20th. HC Wainwright reiterated a "buy" rating and set a $38.00 target price on shares of LENZ Therapeutics in a report on Thursday, May 8th. Finally, Piper Sandler began coverage on LENZ Therapeutics in a report on Monday, April 14th. They issued an "overweight" rating and a $51.00 price target on the stock. Five research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, the company presently has a consensus rating of "Buy" and an average price target of $46.60.

LENZ Therapeutics Stock Performance

LENZ stock traded down $0.62 during midday trading on Monday, hitting $34.57. 280,864 shares of the company's stock were exchanged, compared to its average volume of 197,949. The stock's fifty day moving average price is $30.15 and its 200-day moving average price is $26.52. The company has a market cap of $973.15 million, a PE ratio of -19.53 and a beta of 0.42. LENZ Therapeutics has a one year low of $16.54 and a one year high of $38.93.

Institutional Trading of LENZ Therapeutics

Institutional investors have recently modified their holdings of the company. KLP Kapitalforvaltning AS bought a new stake in shares of LENZ Therapeutics in the fourth quarter valued at about $46,000. Tower Research Capital LLC TRC increased its position in shares of LENZ Therapeutics by 162.3% in the fourth quarter. Tower Research Capital LLC TRC now owns 1,860 shares of the company's stock valued at $54,000 after acquiring an additional 1,151 shares during the last quarter. Virtus ETF Advisers LLC acquired a new stake in shares of LENZ Therapeutics in the fourth quarter valued at about $67,000. Banque Transatlantique SA acquired a new stake in shares of LENZ Therapeutics in the first quarter valued at about $119,000. Finally, GAMMA Investing LLC increased its position in shares of LENZ Therapeutics by 5,254.1% in the first quarter. GAMMA Investing LLC now owns 5,836 shares of the company's stock valued at $150,000 after acquiring an additional 5,727 shares during the last quarter. 54.32% of the stock is currently owned by institutional investors.

LENZ Therapeutics Company Profile

LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.